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Intravenous lidocaine infusion as a
component of multimodal analgesia for
colorectal surgery—measurement of
plasma levels
E. Greenwood1 , S. Nimmo1, H. Paterson1, N. Homer2 and I. Foo1*
Abstract
Background: Growing evidence suggests that intravenous lidocaine as a component of multimodal analgesia
improves recovery after major colorectal surgery. There is little published data regarding ideal dosing and target
plasma concentration in this context, and we wanted to establish our dosing schedule was safe by measuring
blood levels of lidocaine.
Methods: We measured the plasma lidocaine concentration of 32 patients at 30 min, 6 h and 12 h after starting
intravenous lidocaine infusion for analgesia after major colorectal surgery. Patients received a bolus of 1.5 mg kg−1
over 20 min at the time of induction of anaesthesia. This was followed by a continuous infusion of 2% w/v
lidocaine at 3 ml hr−1 (60 mg hr−1) for patients weighing up to 70 kg and 6 ml hr−1 (120 mg hr−1) for patients
weighing over 70 kg, using actual body weight.
Results: The overall mean plasma lidocaine concentration was 4.0 μg ml−1 (range 0.6–12.3 μgml−1). In patients
treated with the higher infusion dose, the mean concentration was 4.6 μgml−1 compared to 3.2 μgml−1 in those patients
on the lower dose. Mean levels were higher at 6 h than 30min and higher again at 12 h. There were no adverse events
or reports of symptoms of local anaesthetic toxicity.
Conclusions: Whilst there were no signs or symptoms of lidocaine toxicity in our patients, there was a wide range
of plasma concentrations including some over 10 μgml−1; a level above which symptoms of toxicity may be expected.
We have changed our dosing protocol to using ideal rather than actual body weight based on these results.
Keywords: Intravenous lidocaine infusion, Colorectal surgery, Plasma lidocaine concentration
Background
Effective and safe acute pain management following
major colorectal surgery is a challenge. Opioid drugs
continue to make up the major component of multi-
modal analgesia, but are associated with significant side
effects—in particular, contributing to postoperative ileus.
The search for safe and effective alternatives and or ad-
juncts continues, and there has been a recent resurgence
of interest in the use of intravenous lidocaine infusions.
Studies to date have shown most success in patients
undergoing major colorectal surgery, which may be due
to both improved pain control but also reduction of ileus
(Weibel et al. 2018; Ventham et al. 2015; Eipe et al.
2016; Rimback et al. 1990). However, questions remain
regarding the details of mode of action and the optimal
dosing schedule.
The colorectal unit at the Western General Hospital in
Edinburgh undertakes around 500 elective colorectal
resections per annum utilising an enhanced recovery
protocol (Tan et al. 2015; Fearon et al. 2005). We have
collected audit data on over 2200 uses of intravenous
lidocaine in these patients, with observed benefits in
pain relief and ileus reduction as in other units. We have
no incidence of local anaesthetic toxic side effects in any
of these patients. Similarly, toxicity has been rare in
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other large published series (Weibel et al. 2018;
Ventham et al. 2015). However, there is little recent
work equating this with perceived safe plasma concen-
trations of lidocaine. Prior to embarking on a more
formal study of the benefits of intravenous lidocaine, we
undertook measurement of plasma lidocaine levels in a
series of patients to assess whether our dosing schedule
provided concentrations within a therapeutic and
non-toxic range as defined by Foldes and Bromage
(Bromage 1961; Foldes et al. 1960). The results are
presented here (Figs. 1 and 2) (Table 1).
Methods
All adult patients undergoing major colorectal resection
in whom the surgical and anaesthetic teams planned to
use intravenous lidocaine, as per local protocol, between
March 2016 and May 2016 were considered for inclusion.
Advice was sought from our local ethics service
regarding the requirement for ethical approval for this
project, and since intravenous lidocaine is a routine part
of care for these patients in our unit, this was considered
to be a safety issue with no requirement for formal
ethical committee review. Verbal consent was obtained
from patients to take blood from arterial lines, as the
assay required arterial blood samples. Patients in whom
arterial lines were not deemed necessary were therefore
not included in the study.
Patients treated with intravenous lidocaine received a
bolus of 1.5 mg kg−1 over 20 min given at the time of
induction of anaesthesia. This was followed by a
continuous infusion of 2% w/v lidocaine at 3 ml hr−1
(60mg hr−1) for patients weighing up to 70 kg and 6ml hr−1
(120mg hr−1) for patients weighing over 70 kg, using
actual, rather than ideal body weight. Patients had con-
tinuous ECG monitoring throughout the duration of
the infusion and staff were educated in monitoring for
the early signs and symptoms of local anaesthetic
toxicity. Absolute contraindications to intravenous
lidocaine were known or suspected allergy to lidocaine
or amide-type local anaesthetics, hypovolaemia and
complete heart block. Infusion was through a dedicated
intravenous cannula and a Y-connector/anti-syphon/
anti-reflux line using an Omnifuse lockable syringe
driver, pre-programmed with the infusion protocol.
Intravenous sodium chloride 0.9% was infused at a
rate of 10 ml hr−1 via the Y-connector.
A total of 85 arterial blood samples were collected and
analysed. Samples were taken at 30 min, 6 h and 12 h
after completion of the initial lidocaine bolus.
There were 20 female and 12 male patients. Eleven
patients were on the lower dose protocol compared to
19 on the higher dose regimen. Two patients had
missing information on samples so could not be
included in the analysis, and some patients did not have
samples taken at all three time intervals. The mean
actual body weight of patients on the lower dose protocol
was 66 kg (range 54–112 kg) and 91 kg (range 70–150 kg)
on the higher dose protocol.
Samples were labelled, centrifuged, frozen and stored
locally at − 80°. They were then sent as a single batch for
analysis of total lidocaine concentration at the Queen’s
Medical Research Institute, Edinburgh.
Lidocaine was extracted from plasma using an SLE+ plate
(Biotage, UK) following enrichment with 3-nitrolidocaine
as an internal standard. Calibration standards ranged from
1 to 2000 ng. Analytes were eluted, reduced to dryness
Fig. 1 Plasma lidocaine levels in patients on the 60mg hr−1 protocol in whom all three levels were obtained (8 patients)
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under nitrogen and reconstituted in water/acetonitrile.
Analysis was carried out by liquid chromatography-tandem
mass spectrometry. Linear regression analysis of calibration
standards, calculated using peak area ratios of lidocaine and
3-nitrolidocaine, was used to determine the concentration
of lidocaine in the samples.
Results
The overall mean plasma lidocaine concentration was
4.0 μg ml−1 (range 0.6–12.3 μgml−1). There were no ad-
verse events or reports of symptoms of local anaesthetic
toxicity from any patients at any time points.
Discussion and conclusion
The uses of lidocaine beyond local and regional tissue
anaesthesia are well established. Given intravenously, it
is effective in obtunding the sympathetic response to
laryngoscopy, in reducing the pain of propofol injection
and it is a class 1b antiarrhythmic agent. Some
centres have demonstrated successful treatment of
chronic neuropathic pain using intravenous lidocaine
(Challapalli et al. 2009). Recent studies are establi-
shing the benefits of postoperative lidocaine infusion,
in particular after major gastrointestinal surgery as a
component of multimodal analgesia (Weibel et al.
2018; Ventham et al. 2015). Benefits include analgesia,
improvement in postoperative gut function and a fee-
ling of euphoria (Weibel et al. 2018; Ventham et al.
2015; Koppert et al. 2004). The exact mechanism of
action of lidocaine in this context is not yet fully
understood, but it is known to have direct analgesic
activity, to reduce central sensitisation to pain and
has anti-inflammatory properties (Lauretti 2008).
Patient safety is of paramount importance, and
although no patients had any symptoms suggestive of
local anaesthetic toxicity in our series, and serious
adverse events are extremely rare in the published meta-
analyses, before progressing the use of intravenous lido-
caine further, we wanted to undertake a series of plasma
measurements to reassure ourselves of the safety of our
technique. This has not been done before in this context
and there is little published evidence available to guide
plasma concentration targets. Measuring levels is not
routinely offered by hospital laboratories in the UK;
however, a very small number of papers describe moni-
toring levels acutely and adjusting treatment based on
results (Weibel et al. 2018; Swenson et al. 2010).
Fig. 2 Plasma lidocaine levels in patients on the 120mg hr−1 protocol in whom all three levels were obtained (15 patients)
Table 1 Mean lidocaine levels with ranges (μgml−1)
Time (hours) 60 mg hr−1 120 mg hr−1 All patients
0.5 2.3 (0.6–4.5) 3.3 (1.3–6.6) 2.8
6 3.0 (0.9–4.9) 5.1 (2.9–10.5) 4.2
12 4.2 (0.8–9.4) 5.3 (1.5–12.3) 4.9
All times 3.2 4.6 4.0
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Currently quoted therapeutic and toxic levels for
plasma lidocaine are largely based on work from 1960
by Foldes and colleagues who gave 12 healthy volunteers
rapid intravenous lidocaine boluses and measured levels
(Foldes et al. 1960). Reported signs and symptoms
included convulsions in two volunteers. A year later,
Bromage published a study measuring levels in seven
patients and correlating them to signs of toxicity
(Bromage 1961). These studies suggested plasma concen-
trations above 5 μgml−1 were associated with neurological
symptoms and levels above 10 μgml−1 with cardiovascular
instability. These papers are still widely referenced and
appear to form the basis upon what is considered the ‘safe’
plasma concentration. Before this, in 1954, a British paper
was published describing a case series of 1000 patients
and administration of up to 750mg per hour of intra-
venous lidocaine. There were three seizures reported, two
of which were blamed on ‘administration error’ rather
than complications of the intended treatment. Plasma
levels were not measured. The authors concluded that
their technique was safe and effective for intraoperative
analgesia (Clive-Lowe et al. 1954). In comparison, the
loading doses and infusion rates in our protocol are
relatively conservative and are based on a studies such as
the one by Swenson and colleagues (Swenson et al. 2010)
who used 2mgmin−1 in patients weighing greater than
70 kg and 1mgmin−1 in patients less than 70 kg. It is
interesting to note that they changed their regimen during
their study after finding that on their original protocol
(using 3mgmin−1 in patients > 70 kg and 2mgmin−1 in
patients < 70 kg), several patients reached potentially toxic
plasma levels (although not all absolute levels are reported
in the paper), including one of their 22 study patients who
experienced disorientation and hallucinations after 4 days
of intravenous lidocaine. This patient was reported to have
had a plasma lidocaine concentration of 6.5 μgml−1 at the
time. It is worth considering that the clinical effects noted
in this case could have been due to the accumulation of
lidocaine metabolites as nonlinear pharmacokinetics is
demonstrable in extended lidocaine infusions (LeLorier et
al. 1977; Weinberg et al. 2015). Our protocol runs for only
12 h so it avoids this potential problem.
Peak plasma concentrations and importantly, clinical
evidence of toxicity, is related to total dose, but also rate
and duration of infusion. A rapid bolus is more likely to
lead to neurological symptoms (Bromage 1961). In pub-
lications describing intravenous lidocaine infusions as a
component of multimodal analgesia for perioperative
pain, there is an assumption that plasma levels are below
the toxic concentrations described by Foldes and Brom-
age. Our results, showing some patients to have lido-
caine levels well above the threshold for toxicity, are
therefore important for a number of reasons. Firstly,
these levels could be associated with both neurological
and cardiovascular toxicity highlighting the importance
of appropriate monitoring and staff training in the
management of toxicity including the use of intralipid.
Secondly, since neither we nor other clinicians routinely
using intravenous lidocaine have seen any symptoms of
toxicity, even mild ones, it is pertinent to ask whether
we need to revise the quoted levels in the context of
much slower administration rates than those used in the
original trials investigating toxic doses. All patients were
under general anaesthesia at the time the first sample
was taken, at 30 min; therefore, symptoms of toxicity
could of course not be assessed. However, we found the
highest levels were at 12 h, and therefore, patients were
fully recovered and able to report symptoms of toxicity,
had they occurred. Additionally, since the optimal infu-
sion rate and duration are not yet known in the context
of postoperative pain management, future work should
include measurement of plasma levels as well as moni-
toring for signs and symptoms of toxicity. On review,
the patients with the highest levels in our study were
emergency cases, who in retrospect may have had organ
impairment and hypovolaemia contributing to altered
lidocaine metabolism and higher plasma concentrations
(deOliveira et al. 2010).
Our original protocol was designed using two fixed
dosing schedules, as well as actual rather than ideal body
weight for doses, in order to reduce the risk of adminis-
tration error and make dosing calculations more straight
forward. In view of finding that heavier patients on the
120 mg hr−1 dose protocol had higher mean levels,
including two patients with plasma concentrations
greater than 10 μg ml−1, and to attempt to create
consistency in plasma concentrations in our patients, we
changed our protocol to use ideal rather than actual
body weight for dosing. We propose future work relating
to intravenous lidocaine should clearly state whether
lean, ideal or actual body weight is used for dosing, as
little published work to date specifies this.
The Western General Hospital is one of the largest colo-
rectal units in the UK. In the last decade, there has been a
major shift from open to laparoscopic surgery. This has
necessitated a change in anaesthetic practice to facilitate
enhanced recovery in this group of patients. Our clinical
experience with intravenous lidocaine over 2200 patients
to date has confirmed benefits in improved quality of
recovery and improved return of gut function. This is
particularly relevant, since the occurrence of ileus in up to
one third of laparoscopic colorectal resection patients is
the single commonest reason for prolonged recovery and
hospital stay. These findings correlate with the meta-ana-
lyses (Weibel et al. 2018; Ventham et al. 2015). We feel
this study makes an important contribution to the
mounting evidence that intravenous lidocaine infusion
after laparoscopic surgery is safe and effective.
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